These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 14592919)

  • 21. Use of mycophenolate mofetil as a rescue agent in the treatment of severe generalized myasthenia gravis in three dogs.
    Abelson AL; Shelton GD; Whelan MF; Cornejo L; Shaw S; O'Toole TE
    J Vet Emerg Crit Care (San Antonio); 2009 Aug; 19(4):369-74. PubMed ID: 25164637
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Medical treatment options for ocular myasthenia gravis.
    Antonio-Santos AA; Eggenberger ER
    Curr Opin Ophthalmol; 2008 Nov; 19(6):468-78. PubMed ID: 18854691
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunosuppression of experimental autoimmune myasthenia gravis by mycophenolate mofetil.
    Janssen SP; Phernambucq M; Martinez-Martinez P; De Baets MH; Losen M
    J Neuroimmunol; 2008 Sep; 201-202():111-20. PubMed ID: 18667242
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. European Mycophenolate Mofetil Cooperative Study Group.
    Lancet; 1995 May; 345(8961):1321-5. PubMed ID: 7752752
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis.
    Howard JF; Bril V; Burns TM; Mantegazza R; Bilinska M; Szczudlik A; Beydoun S; Garrido FJRR; Piehl F; Rottoli M; Van Damme P; Vu T; Evoli A; Freimer M; Mozaffar T; Ward ES; Dreier T; Ulrichts P; Verschueren K; Guglietta A; de Haard H; Leupin N; Verschuuren JJGM;
    Neurology; 2019 Jun; 92(23):e2661-e2673. PubMed ID: 31118245
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Azathioprine and mycophenolate mofetil in myasthenia gravis.
    Vinciguerra C; Milella G; Monastero R; Brighina F; Di Stefano V
    Lancet Neurol; 2024 Aug; 23(8):762. PubMed ID: 39030031
    [No Abstract]   [Full Text] [Related]  

  • 27. A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group.
    Palace J; Newsom-Davis J; Lecky B
    Neurology; 1998 Jun; 50(6):1778-83. PubMed ID: 9633727
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ephedrine treatment for autoimmune myasthenia gravis.
    Lipka AF; Vrinten C; van Zwet EW; Schimmel KJ; Cornel MC; Kuijpers MR; Hekster YA; Weinreich SS; Verschuuren JJ
    Neuromuscul Disord; 2017 Mar; 27(3):259-265. PubMed ID: 28007405
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mycophenolate mofetil therapy in Taiwanese myasthenia gravis.
    Yeh JH; Chen WH; Chiu HC
    Acta Neurol Taiwan; 2008 Sep; 17(3):167-71. PubMed ID: 18975522
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomized controlled trial of methotrexate for patients with generalized myasthenia gravis.
    Pasnoor M; He J; Herbelin L; Burns TM; Nations S; Bril V; Wang AK; Elsheikh BH; Kissel JT; Saperstein D; Shaibani JA; Jackson C; Swenson A; Howard JF; Goyal N; David W; Wicklund M; Pulley M; Becker M; Mozaffar T; Benatar M; Pazcuzzi R; Simpson E; Rosenfeld J; Dimachkie MM; Statland JM; Barohn RJ;
    Neurology; 2016 Jul; 87(1):57-64. PubMed ID: 27306628
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunosuppressive agents for myasthenia gravis.
    Hart IK; Sathasivam S; Sharshar T
    Cochrane Database Syst Rev; 2007 Oct; (4):CD005224. PubMed ID: 17943844
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mycophenolate mofetil - as an adjunctive immunosuppressive therapy in refractory myasthenia gravis: The Singapore experience.
    Prakash KM; Ratnagopal P; Puvanendran K; Lo YL
    J Clin Neurosci; 2007 Mar; 14(3):278-81. PubMed ID: 16597503
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lessons from two trials of mycophenolate mofetil in myasthenia gravis.
    Sanders DB; Siddiqi ZA
    Ann N Y Acad Sci; 2008; 1132():249-53. PubMed ID: 18567876
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Azathioprine and mycophenolate mofetil in myasthenia gravis - Authors' reply.
    Narayanaswami P; Sanders DB
    Lancet Neurol; 2024 Aug; 23(8):762-763. PubMed ID: 39030030
    [No Abstract]   [Full Text] [Related]  

  • 35. Comparison of outcome measures from a trial of mycophenolate mofetil in myasthenia gravis.
    Wolfe GI; Barohn RJ; Sanders DB; McDermott MP
    Muscle Nerve; 2008 Nov; 38(5):1429-1433. PubMed ID: 18949779
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mycophenolate mofetil in AChR-antibody-positive myasthenia gravis: outcomes in 102 patients.
    Hehir MK; Burns TM; Alpers J; Conaway MR; Sawa M; Sanders DB
    Muscle Nerve; 2010 May; 41(5):593-8. PubMed ID: 20405499
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Can mycophenolate mofetil be tapered safely in myasthenia gravis? A retrospective, multicenter analysis.
    Hobson-Webb LD; Hehir M; Crum B; Visser A; Sanders D; Burns TM
    Muscle Nerve; 2015 Aug; 52(2):211-5. PubMed ID: 25906756
    [TBL] [Abstract][Full Text] [Related]  

  • 38. T-cell lymphoproliferative disorder following mycophenolate treatment for myasthenia gravis.
    Dubal DB; Mueller S; Ruben BS; Engstrom JW; Josephson SA
    Muscle Nerve; 2009 Jun; 39(6):849-50. PubMed ID: 19358236
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Primary CNS lymphoma complicating treatment of myasthenia gravis with mycophenolate mofetil.
    Vernino S; Salomao DR; Habermann TM; O'Neill BP
    Neurology; 2005 Aug; 65(4):639-41. PubMed ID: 16116136
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A review of clinical experience with the novel immunosuppressive drug mycophenolate mofetil in renal transplantation.
    Behrend M
    Clin Nephrol; 1996 May; 45(5):336-41. PubMed ID: 8738667
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.